Final Program

68 SUNDAY • MAY 15
P616
P617
P618
Clinical Features and Associated Likelihood of Primary Ciliary
Dyskinesia in Adults /K.M. Sullivan, M.L.A. Daniels, J.J.
Atkinson, T.W. Ferkol, D. Hall, H.-S. Lee, H. Metjian, K.N. Olivier,
M. Rosenfeld, C.E. Milla, M. Zariwala, S.D. Sagel, J. Carson, J.
Krischer, M. Hazucha, M. Knowles, M. Leigh, Genetics Disorders
Of Mucociliary Clearan, p.A1765
Determinants of Respiratory Function in Adults Patients with
Primary Ciliary Dyskinesia/J. Frija-Masson, L. Bassinet, I.
Honore, N. Dufeu, B. Housset, A. Coste, J.-F. Papon, E. Escudier,
P.-R. Burgel, B. Maitre, Creteil, France, p.A1766
Maximal Mid-Expiratory Flow Is a Surrogate Marker of Lung
Clearance Index for Assessment of Adults with
Bronchiectasis/W.-J. Guan, J.-J. Yuan, Y.-H. Gao, H.-M. Li, J.-P.
Zheng, R. Chen, N. Zhong, Guangzhou, China, p.A1767
P619 Baseline Demographic Profile of Subjects of the Phase 3
RESPIRE 2 Trial of Ciprofloxacin Dry Powder for Inhalation
(DPI) in Non-Cystic Fibrosis Bronchiectasis (NCFB)/T.R.
Aksamit, A. De Soyza, E. Operschall, T.-J. Bandel, U. Krahn, E.
Montegriffo, M. Criollo, R.C. Wilson, Rochester, MN, p.A1768
P620
P621
Facilitator:
P622
P623
P624
P625
P626
Prevalence of Airflow Limitation in Patients with
Bronchiectasis, and Its Effect on Acute Exacerbation and the
Decline of Lung Function/J.-M. Kim, S.M. Choi, J. Lee, Y.S. Park,
C.-H. Lee, S.-M. Lee, J.-J. Yim, Y.W. Kim, S.K. Han, C.-G. Yoo,
Seoul, Korea, Republic of, p.A1769
Relationship Between Airway Inflammatory Biomarkers and
Functional Status in Non-Cystic Fibrosis Bronchiectasis/M.A.
Roggi, F.L. Dente, M. Latorre, M. Bilotta, D. Nieri, M.L. Bartoli, S.
Cianchetti, B. Vagaggini, P. Paggiaro, Pisa, Italy, p.A1770
N.M. Quesada, MD, Chicago, IL
Acute Exacerbations of Non-Cystic Fibrosis Bronchiectasis:
What Can Promise Non-Invasive Ventilation for Patients with
Type 2 Respiratory Failure?/A. Sadigov, S. Akhundov, F.
Abdullayev, Baku, Azerbaijan, p.A1771
Pseudomonas Colonization, Lung Function, Computed
Tomography, and Macrolides in Non-Cystic Fibrosis
Bronchiectasis: What Can We Wait from These Dates?/A.
Sadigov, G. Sadigova, S. Huseynova, I. Ashirova, Baku,
Azerbaijan, p.A1772
The Relationship Between Vitamin D Levels and Lung
Function, Clinical Indices, Depression and Anxiety Symptoms
in Adult Patients with Non-Cystic Fibrosis Bronchiectasis/M.
Bekir, D. Kocakaya, S. Olgun Yildizeli, H. Arikan, E. Eryuksel, B.
Bagci Ceyhan, Istanbul, Turkey, p.A1773
Non-Cystic Fibrosis Bronchiectasis in Patients with
Hematologic Malignancy/L.W. Chen, W.B. Karkowsky, S.
Montner, P.J. McShane, S.R. White, M.E. Strek, Chicago, IL,
p.A1774
ORBIT-3 and ORBIT-4: Design of a Phase 3 Program to
Investigate Safety and Efficacy of Pulmaquinr in Non-Cystic
Fibrosis Bronchiectasis (NCFBE) Patients Chronically
Colonized with Pseudomonas Aeruginosa (PA)/A. O’Donnell, D.
Bilton, D. Serisier, A. Wanner, J. Froehlich, P. Bruinenberg, I.
Gonda, Washington, DC, p.A1775
P627
P628
P629
P630
P631
P632
P633
Facilitator:
P634
P635
P636
P637
P638
P639
P640
Profile of Exacerbations Among Patients with Non-Cystic
Fibrosis Bronchiectasis at the State University of Rio de
Janeiro/R.K.R. Leal, R.E.B. Salles, W. Costa, A.B.A. Silva, T.F.
Cruz, B.R.A. Silva, Rio de Janeiro, Brazil, p.A1776
Respiratory Failure After Bronchial Arterial Embolization in
Patients with Cystic Fibrosis: An Institutional Review/J.A.
Town, M.L. Aitken, Seattle, WA, p.A1777
Procalcitonin Levels in Cystic Fibrosis Exacerbations/G. Loh,
A. Skabelund, A. French, J. Morgan, San Antonio, TX, p.A1778
Perfluorinated Gas MRI to Detect Regional Ventilation
Heterogeneity in Cystic Fibrosis/J.L. Goralski, E.O. Akinnagbe,
C. Salazar, R.C. Boucher, Y.Z. Lee, S. Donaldson, Chapel Hill, NC,
p.A1779
Use of Ultra-Low Dose Chest Computed Tomography
Scanning to Detect Emphysema in Patients with Cystic
Fibrosis/G. Dalgleish, H. Sahi, K. Lau, C. Daley, D. Garner, P.
King, Clayton, Australia, p.A1780
Atlas-Based Analysis of MRI Measures of Lung Water Density
to Identify Regional Lung Abnormalities in CF Adults/
R.J. Theilmann, A.R. Elliott, C. Darquenne, D.J. Conrad, La Jolla,
CA, p.A1781
The Impact of Aspergillus Fumigatus and Its Treatment on
Outcomes in Cystic Fibrosis/T. Basnayake, F. Finlayson, A.
Peleg, J. Wilson, T. Kotsimbos, Prahran, Australia, p.A1782
E.T. Naureckas, MD, Chicago, IL
The Genetic Profile of Chinese Patients with Cystic Fibrosis/X.
Tian, Y. Liu, X. Li, X. Zhang, K.-F. Xu, Beijing, China, p.A1783
Fenretinide Normalizes Aberrant Lipid Metabolism and
Prevents Excessive Inflammation During Pulmonary
Exacerbation in Adult Cystic Fibrosis Patients/D. Radzioch, G.
Wojewodka, S. Cupri, P. Colin, R. Pislariu, D. Garic, I. Kianicka, E.
Matouk, Montreal, Canada, p.A1784
How does CPET Compared to Yearly Lung Function Follow-Up
in Adult Cystic Fibrosis Patients/T.S. Hynes, P. Harnett, B.
Casserly, Limerick, Ireland, p.A1785
Severity Index in Pulmonary Exacerbations in Cystic
Fibrosis/L. Diab, R.M. Giron, E. Garcia, C. Marcos, M. Hernandez,
J.L. Justicia, C. Acosta, J. Ancochea, Madrid, Spain, p.A1786
Nebulizer Aerosol Performance and Patient Acceptance in
Cystic Fibrosis/C. Landon, G. Garza, Ventura, CA, p.A1787
Study Design: Effects of Long Term TobrAmycin Inhalation
Solution (TIS) Once Daily on Exacerbation Rate in Patients
with Non-Cystic Fibrosis Bronchiectasis. A Double Blind,
Randomized, Placebo and TIS Twice Daily (open label)
Controlled Trial. The BATTLE/L. Terpstra, J. Altenburg, R.
Duijkers, W.G. Boersma, Alkmaar, Netherlands, p.A1788
Epidemiology And Natural History of Pseudomonas
aeruginosa Infection in Patients with Non-Cystic Fibrosis
Related Bronchiectasis/R. Lim, T. Woo, J. Duong, B. Waddell, C.
Mody, H. Rabin, D.G. Storey, M.D. Parkins, Calgary, Canada,
p.A1789
ATS 2016 • San Francisco